HMB (Beta-Hydroxy Beta-Methylbutyrate)

What is HMB?

HMB stands for beta-hydroxy beta-methylbutyrate. Your body produces small amounts of HMB naturally as a downstream metabolite of leucine, an essential branched-chain amino acid. Roughly 5% of dietary leucine is converted to HMB. Supplemental HMB delivers a far higher concentration than diet alone can provide.

HMB exists in two forms in commerce: HMB-Ca (calcium salt) and HMB-FA (free acid). HMB-FA has somewhat faster pharmacokinetics; the calcium form has the longer and broader research base.

How HMB works

Leucine is the most anabolic amino acid; it signals through the mTOR pathway to drive muscle protein synthesis. HMB, however, acts predominantly through a different lever: it inhibits the ubiquitin-proteasome pathway, the cellular machinery responsible for muscle protein breakdown. That mechanistic distinction matters — HMB is most useful when the body is in a catabolic state and the priority is protecting muscle, not building new tissue.

This is why HMB shows its largest effects in conditions where muscle is at risk: aging, hospitalization, immobilization, energy restriction, and rapid weight loss.

What the evidence shows

The HMB literature is most consistent in catabolic and older-adult contexts, less consistent in resistance-trained young adults.

• A 2018 systematic review and meta-analysis in Nutrients found HMB supplementation in older adults preserved lean body mass during periods of bed rest and caloric restriction [1].
• A 2013 trial in Clinical Nutrition showed HMB plus arginine and glutamine in older adults at risk of muscle loss improved lean mass and grip strength compared with isocaloric controls [2].
• A 2020 randomized trial in Journal of Cachexia, Sarcopenia and Muscle found HMB supplementation during 10 days of bed rest preserved leg lean mass versus placebo, which lost a clinically meaningful amount [3].

Evidence level: moderate — strong for muscle preservation in catabolic states, weaker for hypertrophy in healthy trained young adults.

HMB for menopause, women over 40, and GLP-1 weight loss

Two midlife realities make HMB especially relevant. First, estradiol withdrawal accelerates the loss of type-II muscle fibers and increases baseline protein turnover, meaning women in perimenopause and postmenopause are in a mild but real catabolic drift. Second, the most effective tools for menopausal weight management — energy-restricted diets and GLP-1 medications — both reduce muscle mass as a side effect of overall weight loss.

The literature in GLP-1-induced weight loss is still young, but the mechanism is clear: when total intake drops, protein intake usually drops with it, and the ubiquitin-proteasome system ramps up muscle breakdown. HMB is a logical adjunct precisely because its mechanism (anti-catabolic) maps onto the dominant risk. It is not a replacement for adequate protein intake (1.6–2.2 g/kg/day) or resistance training, both of which remain primary; HMB is a third lever.

For midlife women not on a GLP-1, HMB still has a role in extended caloric deficits, illness recovery, or periods of forced inactivity. See our menopause supplements guide for how it fits alongside protein and resistance training.

Dosage used in research

The standard dose is 3 g/day, typically split as 1 g three times daily with meals. This dose has been used in nearly all positive trials. The effects build over 4–8 weeks. Discuss dosing with your provider if you have liver or kidney disease.

Safety and interactions

HMB is generally well tolerated with no serious adverse events documented across decades of use. It is on the FDA's Generally Recognized as Safe (GRAS) list at the standard dose. No known clinically significant drug interactions.

People with phenylketonuria should check label additives. People with severe liver or kidney disease should discuss supplementation with their clinician.

Where you will find it at kindr

HMB appears in our GLP-1 Shield protocol stack, designed for women losing weight on semaglutide or tirzepatide who want to protect lean mass.

Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026